WESTCHESTER COUNTY LIFE SCIENCES UPDATE

CT1812’s Impact on Alzheimer-Related Biomarkers

Suggests Altering Disease Effect

Recently announced results from a meta-analysis of a portion of the phase 2 SHINE study (NCT03507790) and the complete dataset from the phase 1b SPARC trial (NCT03493282) showed that CT1812, an oral sigma-2 (S2R) receptor modulator, had statistically significant impacts on Alzheimer disease (AD)-related biomarkers. Above all, the findings highlight a prominent role of CT1812 in regulating synaptic and amyloid-ß biology, the study investigators concluded.1,2

These data were presented at AD/PD 2023: the International Conference on Alzheimer’s and Parkinson’s Diseases by Mary Hamby, PhD, vice president of research at Cognition Therapeutics. 

Developed by Purchase’s Cognition Therapeutics, CT1812 is a highly brain-penetrant small molecule modulator of sigma-2 receptor that displaces amyloid-ß oliogomers bound to neuronal synapses 1. The meta-analysis presented leveraged commonalities across trials including same treatment duration (6 months), same patient population (mild to moderate AD), and same methods to assess cerebrospinal (CSF) proteomes. When combining the trials and including patients with available data, the sample size increased from 17-18 to 35, resulting in enough statistical power.

Cognition Announces New Episode of “Conversations” Podcast: Insights for the Primary Care Physician:

Recognizing Dementia with Lewy Bodies

Cognition Therapeutics, Inc. has released its fourth “Conversations” video podcast, a two-part conversation about dementia with Lewy bodies (DLB) focusing on the overlapping symptoms and pathology of DLB, Alzheimer's and Parkinson's diseases. Four neuroscience thought leaders with a wealth of experience in diagnosing and managing dementia share their insights into the nuanced symptoms and signs that help them differentiate DLB from other dementias such as Alzheimer’s disease.

WCBA Program Leader Design Technologies

Rebrands as FirstXFounder

Design Technologies LLC, committed to helping launch early-stage IP based companies, has unveiled a new brand, reflecting the organization’s purpose and continued direction. The organization’s new brand, FirstXFounder, reflects the progress and growth of the programs offered by the company since its inception and its continued commitment and dedication to providing support to founders and early-stage companies.

Design Technologies LLC founded in 2008, is led by entrepreneurs for entrepreneurs, with a mission to deliver entrepreneur education and business networking to emerging life science ventures in the NY Metro area through community centered, technology based economic development (TBED) programs including the Westchester County Biosciences Accelerator and many more.

FirstXFounder delivers expert led programming to foster foundational business skills and meaningful connections necessary to advance.

US FDA Expands Use of Regeneron's Cholesterol

Drug in Young Children

Tarrytown-headquartered Regeneron Pharmaceuticals Inc announced the U.S. Food and Drug Administration had approved the expanded use of its drug in children aged 5 to 11 years to treat an ultra-rare disease that causes high cholesterol.

The drug, Evkeeza, was approved in February 2021 as an additional treatment with other lipid-lowering therapies for patients aged 12 years and above with homozygous familial hypercholesterolemia (HoFH).

The expanded approval makes Regeneron's Evkeeza the first drug to treat kids under 10 with the condition.

Have good news to share with

Westchester’s life sciences ecosystem?

Please let us know.

Email lifesciences@westchestergov.com.